**Appendix 4: Sensitivity / Subgroup Analyses**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Determinant** | **Pooled estimate (all studies)** | **Pooled estimate (excluding high risk studies)** | **Pooled estimate (SSA countries)** | **Pooled estimate (non SSA countries)** |
| Sex | 1.21 [1.16-1.26] | 1.23 [1.17-1.28] | 1.22 [1.18-1.27] | 1.08 [1.03-1.12] |
| Age continuous | 0.98 [0.98-0.99] | 0.98 [0.98-0.99] | 0.99 [0.98-0.99] | \* |
| Education (primary vs none) | 0.89 [0.80-0.98] | NA | NA | NA |
| Education (secondary vs none) | 0.82 [0.71-0.95] | NA | NA | NA |
| Education (tertiary vs none) | 0.76 [0.62-0.94] | NA | NA | NA |
| Relationship status (single vs married) | 1.22 [1.11-1.33] | NA | 1.19 [1.07-1.33] | \* |
| Relationship status (single vs divorced) | 1.11 [0.99-1.24] | NA | 1.09 [0.94-1.28]  | \* |
| Relationship status (divorced vs married) | 1.14 [0.99-1.32] | NA | 1.06 [0.96-1.18] | 1.29 [1.19-1.39]  |
| Employment (unemployed vs employed) | 1.23 [1.09-1.38] | NA | 1.18 [1.05 -1.32] | \* |
| CD4 (≤50 vs 200-350) | 1.13 [0.98-1.30] | NA | 1.18 [1.05-1.32] | \* |
| CD4 (≤100 vs >350) | 1.13 [0.85-1.51] | NA | 1.13 [0.81-1.58] | \* |
| CD4 (≤200 vs >200) | 1.26 [0.94-1.68] | 1.34 [0.97-1.86] | 1.29 [0.89-1.87] | \* |
| CD4 (100-200 vs >350) | 0.97 [0.86-1.10] | NA | 1.00 [0.88-1.14] | \* |
| CD4 (200-350 vs >350) | 0.95 [0.84-1.06] | NA | 0.98 [0.87-1.10] | \* |
| WHO stage (II vs I) | 1.01 [0.95-1.08] | NA | 1.01 [0.95-1.08] | \* |
| WHO stage (III vs I) | 1.06 [0.97-1.16] | NA | 1.05 [0.96-1.15] | \* |
| WHO stage (III vs I/II) | 1.06 [0.99-1.14] | NA | NA | NA |
| WHO stage (IV vs I) | 1.27 [1.08-1.49] | NA | 1.24 [1.05-1.46] | \* |
| WHO stage (IV vs I/II) | 1.16 [1.09-1.25] | NA | NA | NA |
| WHO stage (III/IV vs I/II) | 1.25 [1.16-1.34] | NA | 1.25 [1.16-1.34] | \* |
| Weight BMI (per 1kg/m2 increase) | 0.97 [0.96-0.99] | NA | \* | \* |
| Weight BMI (≤18.5 vs >18.5) | 1.35 [1.26-1.45] | NA | 1.39 [1.32-1.46] | \* |
| Functional status (Bedridden vs working) | 1.46 [1.17-1.83] | NA | NA | NA |
| Functional status (ambulatory vs working) | 1.28 [1.13-1.45] | NA | NA  | NA |
| Tuberculosis (TB vs no TB) | 1.11 [0.95 -1.30] | 1.12 [0.95-1.33] | 1.18 [0.98-1.42] | 0.90 [0.66-1.23]  |
| Adherence | 3.13 [1.81-5.39] | NA | 2.94 [1.64-5.28] | \* |
| Disclosure / stigma | 1.64 [1.24-2.16] | NA | NA | NA |
| Regimen (efavirenz vs nevirapine) | 0.97[0.90-1.04] | NA | 0.98 [0.89-1.07] | 0.94 [0.88-1.01]  |
| Regimen (stavudine vs zidovudine) | 1.06 [0.93-1.21] | NA | 1.10 [0.93-1.31] | 1.02 [0.76-1.32]  |
| Regimen (stavudine vs tenofovir | 1.35 [0.91-2.01] | \* | \* | \* |
| Cotrimoxazol (no vs yes) \* | 1.24 [1.09-1.40] | NA | 1.23 [1.08-1.39] | \* |
| Geographical setting (rural vs urban) | 0.92 [0.61-1.38] | NA | 0.93 [0.59-1.48] | \* |
| Level of care (primary vs secondary) | 0.69 [0.52-0.91] | \* | NA | NA |
| Year of initiation (per 1 year increase) | 1.21 [1.10-1.32] | NA | NA | NA  |
| NA = no high risk studies / all studies from SSA \* = fewer than 3 studies left; no meta-analysis performed |  |